What diseases does Apelvis combined with fulvestrant treat?

Alpelisib is a prescription drug used in combination with fulvestrant to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (her Adult patients with 2)-negative, PIK3CA mutated advanced or metastatic breast cancer detected by an FDA-approved test after progression on an endocrine-based regimen.

The chemical name of Apelvis is (2S)-N1-[4-Methyl- 5-[2-（2, 2, 2-trifluoro-1, 1-dimethylethyl)-4-pyridyl]-2-thiazolyl]-1, 2-pyrrolidine dicarboxamide. Apelixis a white to almost white powder. The molecular formula of Apelvis is C19H22F3N5O2S, and the relative molecular mass is 441.47 g/mol. ApelixFilm-coated tablets are available in three oral strengths, containing 50mg, 150mg and 200mg of Apellis. Tablets also contain hypromellose, magnesium stearate, mannitol, microcrystalline cellulose, and sodium starch glycolate. The film coating contains hypromellose, iron oxide black, iron oxide red, polyethylene glycol/polyethylene glycol (PEG)4000, talc, and titanium dioxide.

Apelvisis a phosphatidylinositol-3-kinase (PI3K) inhibitor, mainly has inhibitory activity against PI3Kα. In in vitro and in vivo models, encoding the PI3Kcatalyticα subunit (PIK3CA) gene gain-of-function mutations lead to activation of PI3Kα and Akt signaling, cell transformation, and tumorigenesis. In breast cancer cell lines, Apelvis inhibits phosphorylation of PI3K downstream targets, including Akt, and shows activity in cell lines harboring PIK3CA mutations. In vivo, Apelvis inhibits the PI3K/Akt signaling pathway and reduces tumor growth in xenograft models, including breast cancer models. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.